Access cutting-edge grin-related neurodevelopmental disorder treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Boston location
Preparing your pre-screening questions…
Access grin-related neurodevelopmental disorder specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related grin-related neurodevelopmental disorder treatment provided free
Check if you qualify for this grin-related neurodevelopmental disorder clinical trial in Boston, MA
No-Cost Study Care
Local to Boston
Convenient for MA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant. This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort). Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil. The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2. The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.
Sponsor: GRIN Therapeutics, Inc.
Yes, this clinical trial (NCT07224581) has an active research site in Boston, MA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for grin-related neurodevelopmental disorder treatment options in Boston, MA, this clinical trial (NCT07224581) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced grin-related neurodevelopmental disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all grin-related neurodevelopmental disorder clinical trials near you to find additional studies recruiting in your area.
See all erectile dysfunction clinical trials recruiting in Boston — not just this study.
Browse Erectile Dysfunction Trials in Boston →